The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Arginine vasopressin (AVP) is a cyclic nonapeptide synthesized exclusively by neurosecretory cells of the central nervous system (CNS). Two functionally distinct vasopressinergic systems can be defined based on differences in the sites of action and release of AVP. The peripheral vasopressinergic system encompasses the sites of action for AVP released into peripheral circulation (e.g. vascular smooth muscle, liver, kidney) from nerve terminals in the posterior pituitary. Peripherally circulating AVP is responsible for the classic endocrine functions ascribed to this neurohormone (e.g. vasoconstriction, glycogen metabolism, antidiuresis). The central vasopressinergic system, on the other hand, includes the sites of AVP synthesis and release within the CNS, where AVP acts as a neuromodulator/neurotransmitter regulating an array of CNS-mediated functions (e.g. learning and memory, neuroendocrine reactivity, social behaviors, circadian rhythmicity, thermoregulation, and autonomic function). Historically, pharmaceutical interest has focused on drug development efforts that sought to exploit the peripheral effects of AVP. Evidence, however, from clinical studies and animal models of CNS disorders has directly implicated disturbances in vasopressinergic activity in the pathophysiology of a number of human psychiatric disorders (mood, anxiety, and cognitive disorders). This review will examine the available evidence of central vasopressinergic system involvement in psychiatric disorders, and the potential opportunities for development of novel psychopharmaceuticals around this system will be discussed. Specific lines of evidence will be presented which rationalize each AVP receptor subtype (V(1)R or V(1a), V(2)R, V(3)R or V(1b)) as a molecular target for particular psychiatric indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Sawchenko, P. E., & Swanson, L. W. (1982) · Journal of Comparative Neurology · doi:10.1002/cne.902050306 · Cited by 1,150
Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin
Gillies, G. E., Linton, E. A., & Lowry, P. J. (1982) · Nature · doi:10.1038/299355a0 · Cited by 965 · cited 1×
“Acting through vasopressinergic receptors expressed on adenohypophyseal corticotrophs, primarily of the V3R (V 1b) subtype, AVP acts synergistically with corticotropin releasing factor (CRF) to stimulate adrenocorticotropin hormone (ACTH) release from the anterior pituitary into the peripheral circulation.[39] Vasopre…”
BackgroundSynthesis, transport, and release of posterior pituitary hormones
Brownstein, M. J., Russell, J. T., & Gainer, H. (1980) · Science · doi:10.1126/science.6153132 · Cited by 838 · cited 1×
“Processing of ppAVP is believed to occur during axonal transport of the peptide along the secretory pathway, which extends from the endoplasmic reticulum (ER) to the secretory granules (SC) [16].”
BackgroundRaadsheer, F. C., Hoogendijk, W. J. G., Stam, F. C., Tilders, F. J. H., & Swaab, D. F. (2008) · Neuroendocrinology · doi:10.1159/000126778 · Cited by 667
de Vries, G. J., & Buijs, R. M. (1983) · Brain Research · doi:10.1016/0006-8993(83)90855-7 · Cited by 565 · cited 2×
“The importance of the PVN to homeostatic regulation of autonomic functions suggests that these projections are responsible for vasopressinergic control of autonomic activity and nociception at the spinal level.”
BackgroundRivier, C., & Vale, W. (1983) · Nature · doi:10.1038/305325a0 · Cited by 539 · cited 1×
“Although AVP is considered to be a weak secretagogue of ACTH alone, it does act synergistically with CRF at the level of corticotrophs to potentiate ACTH release from the ‘rapidturnover’ pool [125, 126].”
BackgroundBielsky, I. F., Hu, S.-B., Szegda, K. L., Westphal, H., & Young, L. J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300360 · Cited by 531
Cellular Mechanisms of Social Attachment
Young, L. J., Lim, M. M., Gingrich, B., & Insel, T. R. (2001) · Hormones and Behavior · doi:10.1006/hbeh.2001.1691 · Cited by 523 · cited 1×
“AVP studies in voles has featured some of the more provocative work in the field by Insel and Young, who have helped to establish the importance of central vasopressinergic function to differences in affiliative behavior and social attachment between monogamous and non-monogamous species of prairie voles [123, 124].”
BackgroundMolecular cloning and expression of a rat Via arginine vasopressin receptor
Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477
Cited by
Neumann, I. D., & Landgraf, R. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.08.004 · Cited by 954
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02303.x · Cited by 423
Sex differences in oxytocin and vasopressin: Implications for autism spectrum disorders?
CARTER, C. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.08.025 · Cited by 432
Gonadal steroid hormones and the hypothalamo–pituitary–adrenal axis
Handa, R. J., & Weiser, M. J. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.11.001 · Cited by 408
Non-peptide arginine-vasopressin antagonists: the vaptans
Decaux, G., Soupart, A., & Vassart, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60695-9 · Cited by 376
Metadata
- Authors
- Ring, R.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-01-01
- Volume
- 11
- Issue
- 2
- Pages
- 205-225
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W1974923615
- Cited by
- 139
- References
- 49
- FWCI
- 18.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development. https://app.cochat.ai/papers/10.2174/1381612053382241
- The paper
- Ring, R. (2005). The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053382241
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.